Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 7Fallopian Tube Neoplasms 4Melanoma 3Breast Neoplasms 3Stomach Neoplasms 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Liver Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Adenocarcinoma 1

Interventions

Flow Cytometry 3Methylprednisolone 2Immunologic Techniques 2Alemtuzumab 2sargramostim 1saracatinib 1resiquimod 1poly ICLC 1pembrolizumab 1liposomal doxorubicin 1dexamethasone acetate 1dexamethasone 21-phosphate 1cediranib 1aldesleukin 1Therapeutics 1Tacrolimus 1Psychiatric Rehabilitation 1Prednisone 1Moxifloxacin 1Microarray Analysis 1Interleukin-12 Subunit p35 1Interferon-alpha 1Immunoenzyme Techniques 1Granisetron 1Gene Expression Profiling 1ER 30346 1Dexamethasone 1Deferasirox 1Data Collection 1Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × poly ICLC × Gynecologic × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡